Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19
+
B cells from PBM...
Alternative Titles
Full title
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0cddf17a9e6a4d6090ed118300ef3ebf
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0cddf17a9e6a4d6090ed118300ef3ebf
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-018-30358-0
